Oncology
24 drugs are in development for Cancer.
- Companies
- 15
- Clinical trials
- 156
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(4)
Phase 2(3)
| Drug | Company |
|---|---|
| firi-cel | CARGO Therapeutics, Inc. (CRGX) |
| larotrectinib | ARRAY BIOPHARMA INC (ARRY) |
| tarextumab | OncoMed Pharmaceuticals Inc (OMED) |
Phase 1(7)
| Drug | Company |
|---|---|
| gsk4381562 | Surface Oncology, Inc. (SURF) |
| imc-p115c | Immunocore Holdings plc (IMCR) |
| ipafricept | OncoMed Pharmaceuticals Inc (OMED) |
| mt-8421 | Molecular Templates, Inc. (MTEM) |
| nzv930 | Surface Oncology, Inc. (SURF) |
| vantictumab | OncoMed Pharmaceuticals Inc (OMED) |
| wtx-518 | Werewolf Therapeutics, Inc. (HOWL) |
Preclinical(5)
| Drug | Company |
|---|---|
| bnc105 | Neuphoria Therapeutics Inc. (NEUP) |
| sra737 | Sierra Oncology, Inc. (SRRA) |
| srf114 | Surface Oncology, Inc. (SURF) |
| wtx-1011 | Werewolf Therapeutics, Inc. (HOWL) |
| wtx-2022 | Werewolf Therapeutics, Inc. (HOWL) |
Unknown(1)
| Drug | Company |
|---|---|
| picoplatin | ACCELERATED PHARMA, INC. (ACCP) |
Phase 1/Phase 2(4)
| Drug | Company |
|---|---|
| inkmune | Inmune Bio, Inc. (INMB) |
| sns-102 | Faeth Therapeutics, Inc. (FTH) |
| sns-103 | Faeth Therapeutics, Inc. (FTH) |
| sns-201 | Faeth Therapeutics, Inc. (FTH) |
About this indication
Cancer context
Oncology·MeSH: Neoplasms (D009369)
Narrower concept of MeSH descriptor Neoplasms
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Cancer?
BioSniper tracks 24 drugs in development for Cancer across 15 companies.
How many clinical trials target Cancer?
There are 156 clinical trials targeting Cancer tracked by BioSniper.
What is the prevalence of Cancer?
The estimated prevalence of Cancer is approximately 75.0 per 100,000 population.